Future Science Group

The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the patiet–doctor relationship, patient care and outcomes. The authors believe that this podcast series and associated manuscript will aid both patients and healthcare professionals to impro...

The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the patient–doctor relationship, patient care and outcomes. The authors believe that this podcast series and associated manuscript will aid both patients and healthcare professionals to impr...

The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the patient–doctor relationship, patient care and outcomes. The authors believe that this podcast series and associated manuscript will aid both patients and healthcare professionals to impr...

Christopher Lieu, co-director of gastrointestinal medical oncology and the associate director for clinical research at the University of Colorado Cancer Center (CO, USA) discusses the importance of biomarker testing in metastatic colorectal cancer to inform personalized patient care. Find the article on Taylor & Francis - www.doi.org/10.2217/fon-2022-1293

Over the past two decades, HER2-positive breast cancer has undergone a dramatic transformation in oncology. In this interview, Cristina Saura (Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Spain) reflects on witnessing this evolution firsthand, from the introduction of trastuzumab to today's expanding arsenal of HER2-directed agents. Saura discusses the current challen...

In this interview, Imogen Locke (The Royal Marsden NHS Foundation Trust, UK) discusses the evolving role of stereotactic ablative radiotherapy (SABR) in oligometastatic and oligoprogressive breast cancer. Locke explains the distinction between these two clinical scenarios, how timing and patient selection influence treatment decisions, and emerging evidence around metastasis-directed radiotherapy...

First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study by Taylor & Francis Group

In this podcast episode, the speakers discuss how the findings from the EMBARK clinical trial could translate into real world practice.

This podcast focuses on the real-world implications of these EMBARK findings for clinical practice.

This podcast features two of the investigators from the international, randomized, Phase III EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen deprivation therapy alone, in patients with nonmetastatic castration-sensitive prostate cancer and biochemical recur...

In this interview, discover discuss key findings from the DESTINY-Breast09 trial and their implications for clinical practice, including practical advice for oncologists exploring treatment sequencing strategies with T-DXd.

Meet Giorgi Kobidze, your 2026 BRSA finalist.

Meet Richa Pandey, your 2026 BRSA finalist.

Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study by Taylor & Francis Group

Meet Dakshat Trivedi, your 2026 BRSA finalist.

Meet Ethan Sanford, your 2026 BRSA finalist.

Harmonizing scientific innovation, patient care and regulation in advanced therapies: a podcast with Patrice Faloye by Taylor & Francis Group

In this podcast, Deborah Ojutalayo discusses targeted gene therapies for frontotemporal dementia caused by mutations in the GRN gene.

In this podcast, Guillermo explores the development and diverse applications of citrate-based biomaterials, pioneered by his lab, Ameer Labs. He highlights the versatility and potential of these biomaterials, providing examples such as their use in bone and cartilage regeneration. Guillermo also delves into exciting advancements in tissue and regenerative engineering that aim to address significan...

In this podcast, Baba delves into his expertise in hematology, sharing what inspired his journey into this field of research. He also discusses the Academy for Sickle Cell and Thalassaemia (ASCAT) Conference, which he founded to unite experts and professionals working to tackle hematological disorders like sickle cell disease and thalassemia.

Hello and welcome to the latest episode of OCTalks, the podcast series from Oncology Central. I am Jade Parker, Senior Editor of Oncology Central. Today I am joined by Leanne Bailey who is Branch Director of the Community Outreach Research and Engagement branch of the NCI’s Center to Reduce Cancer Health Disparities. In this interview, we will discuss contributing factors to early onset cancers, h...

Trends, tools and transformation: the evolution of flow cytometry in bioanalysis by Taylor & Francis Group

115 analytes, one panel: a conversation on innovation in biomarker discovery by Taylor & Francis Group

Exploring biomarker testing in clinical research

Join Tara Crawford-Parks, PhD, Director for Translational R&D and Product Enablement at DNA Genotek, to explore the potential of first void urine biomarkers in clinical diagnostics. Discover how this non-invasive sampling method is transforming HPV screening and opening new possibilities for early disease detection in oncology and infectious diseases. Learn about the science behind first void urin...